Join
Live feed
·
PRReleasevia Quantisnow
Agenus Inc. logo

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

ByQuantisnow·Wall Street's wire, on your screen.
AGEN· Agenus Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AGEN (Agenus Inc.) and more on Quantisnow.